机构：[1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China[2]Institute of ClinicalRadiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany[3]Department of Medicine, Medical University of Vienna, Vienna, Austria[4]Medical Innovation and Management, Steinbeis University Berlin,Germany[5]Radiology Department, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China[6]Division ofThoracic Oncology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany[7]Division of Respiratory Medicine and ThoracicOncology, Ludwig-Maximilians-University of Munich Thoracic Oncology Centre, Munich, Germany[8]Guangdong General Hospital, Lung CancerInstitute, Guangzhou 510080, China广东省人民医院[9]Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[10]Departmentof Radiology, Beijing Union Medical College Hospital, Beijing 100730, China[11]Department of Respiratory, the Fourth Military Medical UniversityXijing Hospital, Xi’an 710032, China[12]Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China首都医科大学宣武医院[13]Department of Oncology, Tumor Hospital of Jiangsu Province, Nanjing 210000, China[14]Department of Oncology, Xinqiao Hospital of ThirdMilitary Medical University, Chongqing 400037, China[15]Division of Thoracic Oncology,University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany[16]Division of Surgical Oncology and Thoracic Surgery,University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
The first Chinese-German Lung Cancer Expert Panel was held in November 2015 one day after the 7th Chinese-German Lung Cancer Forum, Shanghai. The intention of the meeting was to discuss strategies for the diagnosis and treatment of lung cancer within the context of lung cancer screening. Improved risk classification criteria and novel imaging approaches for screening populations are highly required as more than half of lung cancer cases are false positive during the initial screening round if the National Lung Screening Trial (NLST) demographic criteria [>= 30 pack years (PY) of cigarettes, age >= 55 years] are applied. Moreover, if the NLST criteria are applied to the Chinese population a high number of lung cancer patients are not diagnosed due to non-smoking related risk factors in China. The primary goal in the evaluation of pulmonary nodules (PN) is to determine whether they are malignant or benign. Volumetric based screening concepts such as investigated in the Dutch-Belgian randomized lung cancer screening trial (NELSON) seem to achieve higher specificity. Chest CT is the best imaging technique to identify the origin and location of the nodule since 20% of suspected PN found on chest X-ray turn out to be non-pulmonary lesions. Moreover, novel state-of-the-art CT systems can reduce the radiation dose for lung cancer screening acquisitions down to a level of 0.1 mSv with improved image quality to novel reconstruction techniques and thus reduce concerns related to chest CT as the primary screening technology. The aim of the first part of this manuscript was to summarize the current status of novel diagnostic techniques used for lung cancer screening and minimally invasive treatment techniques for progressive PNs that were discussed during the first Chinese-German Lung Cancer. This part should serve as an educational part for the readership of the techniques that were discussed during the Expert Panel. The second part summarizes the consensus recommendations that were interdisciplinary discussed by the Expert Panel.
第一作者机构：[1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China
通讯作者：
通讯机构：[1]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200090, China[15]Division of Thoracic Oncology,University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany[*1]Division of Thoracic Oncology, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, D-68167 Mannheim, Germany.[*2]Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507, Zhengmin Road, Shanghai 200433, China
推荐引用方式(GB/T 7714)：
Su Chunxia,Meyer Mathias,Pirker Robert,et al.From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel[J].TRANSLATIONAL LUNG CANCER RESEARCH.2016,5(4):377-388.doi:10.21037/tlcr.2016.07.09.
APA：
Su, Chunxia,Meyer, Mathias,Pirker, Robert,Voigt, Wieland,Shi, Jingyun...&Roessner, Eric Dominic.(2016).From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel.TRANSLATIONAL LUNG CANCER RESEARCH,5,(4)
MLA：
Su, Chunxia,et al."From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert Panel".TRANSLATIONAL LUNG CANCER RESEARCH 5..4(2016):377-388
